DE60038624D1 - Methoden zur behandlung von festen tumoren und metastasen mit gentherapie - Google Patents

Methoden zur behandlung von festen tumoren und metastasen mit gentherapie

Info

Publication number
DE60038624D1
DE60038624D1 DE60038624T DE60038624T DE60038624D1 DE 60038624 D1 DE60038624 D1 DE 60038624D1 DE 60038624 T DE60038624 T DE 60038624T DE 60038624 T DE60038624 T DE 60038624T DE 60038624 D1 DE60038624 D1 DE 60038624D1
Authority
DE
Germany
Prior art keywords
gene therapy
metastases
methods
solid tumors
treating solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038624T
Other languages
English (en)
Other versions
DE60038624T2 (de
Inventor
Carlos Estuard Aguilar-Cordova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AQUILAR-CORDOVA CARLOS
Original Assignee
AQUILAR-CORDOVA CARLOS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AQUILAR-CORDOVA CARLOS filed Critical AQUILAR-CORDOVA CARLOS
Publication of DE60038624D1 publication Critical patent/DE60038624D1/de
Application granted granted Critical
Publication of DE60038624T2 publication Critical patent/DE60038624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60038624T 1999-10-07 2000-10-07 Methoden zur behandlung von festen tumoren und metastasen mit gentherapie Expired - Lifetime DE60038624T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15806899P 1999-10-07 1999-10-07
US158068P 1999-10-07
PCT/US2000/027547 WO2001024684A2 (en) 1999-10-07 2000-10-07 Methods for treatment of solid tumors and metastasis by gene therapy

Publications (2)

Publication Number Publication Date
DE60038624D1 true DE60038624D1 (de) 2008-05-29
DE60038624T2 DE60038624T2 (de) 2009-06-10

Family

ID=22566564

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038624T Expired - Lifetime DE60038624T2 (de) 1999-10-07 2000-10-07 Methoden zur behandlung von festen tumoren und metastasen mit gentherapie

Country Status (7)

Country Link
EP (1) EP1223952B1 (de)
JP (2) JP5557974B2 (de)
AT (1) ATE392210T1 (de)
AU (1) AU7862600A (de)
CA (1) CA2386374A1 (de)
DE (1) DE60038624T2 (de)
WO (1) WO2001024684A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
JP2005535676A (ja) * 2002-07-19 2005-11-24 ラドウィッグ・インスティテュート・フォー・キャンサー・リサーチ 腫瘍の処置における放射免疫療法の効果の増強
EP1687032B1 (de) 2003-11-14 2010-02-24 Genvec, Inc. Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
JP4560629B2 (ja) * 2005-03-31 2010-10-13 国立大学法人 筑波大学 腫瘍壊死誘導療法の抗腫瘍効果増強剤
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
EP3268362B1 (de) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituierte pyridine und verwendungen davon
CA3002381A1 (en) 2015-10-21 2017-04-27 Teclison Limited Compositions and methods for immune-mediated cancer therapy
EP3205356A1 (de) * 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Plasmidexpressionsvektor zur codierung von humanem interleukin 12 unter transkriptionskontrolle von p21-promotor und ohne antibiotikaresistenz für krebsgentherapie und andere verwendungen davon
EP3810109A4 (de) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. Zusammensetzungen und verfahren zur hemmung von cd73
SG11202104208RA (en) 2018-10-30 2021-05-28 Peloton Therapeutics Inc Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
JP2023526332A (ja) 2020-05-15 2023-06-21 アルゲン バイオテクノロジーズ，インク． 特定の化学組成物およびその使用方法
BR112022025512A2 (pt) * 2020-06-15 2023-01-17 Kortuc Inc Sensibilizador para tratamento de câncer
KR102570785B1 (ko) * 2021-05-06 2023-08-24 연세대학교 산학협력단 화학방사선요법에 대한 정보 제공 방법 및 이를 적용한 디바이스

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
EP0973926A1 (de) * 1997-03-14 2000-01-26 Selective Genetics, Inc. Adenovirale vektoren mit verändertem tropismus
WO1999038992A1 (en) * 1998-02-03 1999-08-05 Baylor College Of Medicine Synergism between thymidine kinase gene therapy and topoisomerase i and topoisomerase ii inhibitors

Also Published As

Publication number Publication date
JP2012001566A (ja) 2012-01-05
WO2001024684A3 (en) 2001-10-25
JP2003528813A (ja) 2003-09-30
CA2386374A1 (en) 2001-04-12
ATE392210T1 (de) 2008-05-15
WO2001024684A2 (en) 2001-04-12
JP5557974B2 (ja) 2014-07-23
AU7862600A (en) 2001-05-10
EP1223952A4 (de) 2004-12-08
EP1223952A2 (de) 2002-07-24
EP1223952B1 (de) 2008-04-16
DE60038624T2 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
DE60038624D1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
IL178042A0 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
RU2014121335A (ru) Иммуногенное лечение рака
EP0719150A4 (de) Zellulärer impfstoff und verwendungsmethoden für die behandlung von malignen, soliden tumoren
WO1999051263A3 (en) Methods and modified cells for the treatment of cancer
EA202192757A1 (ru) Способ лечения опухолей
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
NO20002412L (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
UA88294C2 (ru) ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
MX2023010825A (es) Metodos para tratar el cancer con anticuerpos anti-ilt3.
DE60212415D1 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
ATE383154T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
FitzGerald et al. Prostate carcinoma: opportunities for translational research
AU2003229876A1 (en) Tumour associated antigens
MX2021015802A (es) Terapia de combinacion.
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
WO2001028573A3 (en) Monocyte conditioned medium for cancer treatment
MD2378F1 (en) Method of determining the parameters for cryoapplication
CY1116323T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ TNFα-ΣΧΕΤΙΖΟΜΕΝΩΝ ΔΙΑΤΑΡΑΧΩΝ
UA40084A (uk) Спосіб лікування занедбаних форм раку молочної залози без наявності віддалених метастазів

Legal Events

Date Code Title Description
8364 No opposition during term of opposition